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Tulehdusta välittäviin sytokiineihin kuuluvan interleukiini 1β (IL-1β):n kohonneen systeemisen pitoisuuden 
on arveltu edesauttavan insuliiniresistenssin kehittymistä ja johtavan haiman β-solujen toimintahäiriöihin. 
IL-1β:n sisäsyntyisellä vastavaikuttajalla, interleukiini 1 reseptoriantagonistilla (IL-1RA), on puolestaan 
esitetty olevan suojaava rooli mainittujen fenotyyppien kehittymisessä päinvastaisten vaikutustensa 
ansiosta.  
 
IL-1RA:n suojaavan roolin havainnollistamiseksi työssä Genetic determinants of circulating interleukin-1 
receptor antagonist levels and their association with glycemic traits tunnistettiin veren IL-1RA- pitoisuuteen 
assosioituvia geneettisiä variantteja, minkä jälkeen selvitettiin näiden yhteyttä glukoosi- ja 
insuliinimetaboliaan liittyvien muuttujien-, sekä immunologisten muuttujien pitoisuuksiin. 
 
Yhteensä 11 tutkimuskohorttia käsittäneessä genominlaajuisessa assosiaatioanalyysissä ja meta-analyysissä 
tunnistettiin kaksi toisistaan riippumatonta yhden nukleotidin polymorfismia (SNP), jotka assosioituivat 
itsenäisesti veren IL-1RA- pitoisuuteen: rs4251961 lokuksessa IL1RN (n = 13 955, P = 2,76e-21) ja rs6759676 
lokuksen IL1F10 läheisyydessä (n = 13 994, P = 1,73e-17). Kyseisten varianttien yhteinen selitysosuus IL-1RA:n 
varianssista oli 2,0 %. Molemmat variantit assosioituivat mataliin C-reaktiivisen proteiinin (CRP) systeemisiin 
pitoisuuksiin. Tämän lisäksi rs6759676 assosioitui mataliin paastoinsuliinin pitoisuuksiin, sekä matalaan 
insuliiniresistenssiin (HOMA-IR).  
 
Tutkimuksemme osoittaa, että geneettisesti säädelty IL-1RA:n kohonnut pitoisuus saattaa suojata 
insuliiniresistenssin kehittymiseltä. Tulokset tukevat myös näkemystä elimistön tulehdusreaktion ja 
insuliiniresistenssin kehittymisen kausaliteetista, joskin lisätutkimukset ovat tarpeen ilmiön paremmaksi 
ymmärtämiseksi. 
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Abstract  
The pro-inflammatory cytokine interleukin (IL)-1β is implicated in the development of insulin 
resistance and beta-cell dysfunction, whereas higher circulating IL-1 receptor antagonist (IL-
1RA – an endogenous inhibitor of IL-1β - has been suggested to improve glycemia and beta-
cell function in patients with type 2 diabetes. In order to elucidate the protective role of IL-
1RA, this study aimed to identify genetic determinants of circulating IL-1RA concentration 
and to investigate their associations with immunological and metabolic variables related to 
cardiometabolic risk. In the analysis of 7 discovery and 4 replication cohort studies, two 
single nucleotide polymorphisms (SNPs) were independently associated with circulating IL-
1RA concentration (rs4251961 at the IL-1RN locus, n=13,955, P=2.76x10-21; and rs6759676, 
closest gene locus IL1F10, n=13,994, P=1.73x10-17). The proportion of the variance in IL-
1RA explained by both SNPs combined was 2.0%. IL-1RA-raising alleles of both SNPs were 
associated with lower circulating C-reactive protein concentration. The IL-1RA-raising allele 
of rs6759676 was also associated with lower fasting insulin and lower homeostasis model 
assessment insulin resistance (HOMA-IR). In conclusion, we show that circulating IL-1RA 
levels are predicted by two independent SNPs at the IL-1RN and IL-1F10 loci and that 
genetically raised IL-1RA may be protective against the development of insulin resistance.    
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The balance between the potent pro-inflammatory cytokine interleukin (IL)-1β and its 
endogenous inhibitor IL-1 receptor antagonist (IL-1RA) is crucial for the regulation of the 
immune system in health and disease (1-3). Inborn genetic deletion of a region spanning the 
IL1RN gene that encodes IL-1RA leads to severe auto-inflammatory disease (4,5), and 
recombinant IL-1RA has been used for years to treat inflammatory conditions such as 
rheumatoid arthritis (3). More recently, a small, randomized clinical trial demonstrated that 
treatment with recombinant IL-1RA improved glycemic control and beta-cell function in 
patients with type 2 diabetes (T2D) (6). Although T2D is not characterized by the classical 
symptoms of inflammation present in diseases such as rheumatoid arthritis, IL-1β has been 
identified as a proinflammatory cytokine that may underlie the link between metabolic 
overload leading to glucotoxicity, lipotoxicity, oxidative stress, organelle stress and amyloid 
deposition on the one hand, and insulin resistance and beta-cell-dysfunction on the other hand 
(7,8).  
Observational studies show that IL-1RA concentrations are increased more than a decade 
before diagnosis of T2D, and this is accentuated during the six years preceding the clinical 
onset of disease when compared with non-diabetic controls (9-12). Therefore, IL-1RA shows 
similarities to cytokines from the transforming growth factor (TGF) superfamily, TGF-β1 and 
macrophage inhibitory cytokine (MIC)-1, which are also present at elevated levels in 
individuals who will develop T2D (13-15). In contrast, IL-1RA differs from the anti-
inflammatory adipokine, adiponectin, of which expression and release from adipocytes is 
downregulated prior to the onset of T2D (16-18).  
IL-1RA expression and secretion are regulated by pro-inflammatory cytokines with IL-1β 
being the most prominent trigger. In addition, IL-1β expression is also induced by metabolic 
stimuli such as glucose and free fatty acids (19-22). Genetic determinants of IL-1RA levels in 
the IL1RN and IL1F10 loci and the IL1B locus encoding IL-1β have been described (23-30). 
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There is evidence that these variants not only regulate systemic levels of IL-1RA, but also 
associate with fat mass and concentrations of glucose, insulin and several immune mediators 
in the circulation (23,24,26-28). So far, it is unknown whether IL-1RA levels are determined 
by additional gene variants outside the loci above.  
Therefore, the aims of the present study were to (i) identify novel genetic determinants of 
circulating IL-1RA in large population-based cohorts, and (ii) to assess common underlying 
biological pathways by investigating their associations with gene expression levels and 
metabolic and immunological variables that contribute to cardiometabolic risk.   
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RESEARCH DESIGN AND METHODS 
Cohorts. We assembled 7 studies for the discovery analysis, totalling up to 9,285 individuals 
of European ancestry. Replication included 4 cohorts comprising up to 7,938 individuals 
Local research ethics committees approved all studies and all participants gave informed 
consent to each original study. Discovery and follow-up cohort characteristics as well as 
information on genotyping and phenotyping are given by cohort. 
Whitehall II Study 
(i) Study population: The Whitehall II (WHII) study recruited 10,308 men and women 
between 1985 and 1989 from 20 London-based civil service departments. Clinical 
measurements were taken at 5-year intervals. Currently, clinical data is available from 4 
phases (phase 1: 1985-1988, phase 3: 1991-1993, phase 5: 1997-1999 and phase 7: 2003-
2004). Blood samples for DNA were collected in 2002–2004 from more than 6000 
participants. IL-1RA measurements were available from a case-cohort subset in phase 3. 
Briefly, a random sample was drawn from the source population of 8816 individuals who had 
attended the phase 3 examination. We excluded participants with prevalent T2D at phase 3 
(n=42), missing follow-up data on diabetes (n=552), missing data for key variables (CRP 
[limited to subjects with CRP<10 mg/l], weight, waist circumference, cholesterol, 
triglycerides, fasting glucose, fasting insulin) at baseline (n=2018) or during follow-up 
(phases 5 and 7; n=3049), leading to a case-cohort of 2810 subjects.  
(ii) IL-1RA measurements: IL-1RA serum concentrations were measured using the Quantikine 
ELISA kit (R&D Systems, Wiesbaden, Germany). Mean intra- and inter-assay coefficients of 
variation (CVs) were 2.6% and 7.9%, respectively. The limit of detection was 14 pg/ml. All 
samples gave values above the limit of detection.      
(iii) Genotyping and quality control: In 2010, 3413 samples from the WHII study were 
genotyped using the Illumina Metabochip. A subset of these had also previously been 
genotyped using the Illumina HumanCVD array. The combined data used in this analysis 
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consisted of SNP data for 3178 Caucasian individuals genotyped on both platforms. After 
filtering the data for outliers (as identified by multi-dimensional scaling), cryptic relatedness, 
ambiguous sex, and sample and SNP call rates (<95%), genetic data for 236,426 SNPs in 
3102 individuals was available for analysis, of whom 2160 had IL-1RA measurements.  
(iv) Measurement of metabolic and immunological traits: Blood samples were collected from 
participants before and at the end of the 2-h oral glucose tolerance test. Blood glucose was 
measured with the glucose oxidase method (YSI Corporation, Yellow Springs, OH). Serum 
insulin was measured with an in-house human insulin radioimmunoassay/ELISA 
(DakoCytomation Ltd, Ely, UK). C-reactive protein (CRP) was measured with a high-
sensitivity immunonephelometric assay in a BN ProSpec nephelometer (Dade Behring, 
Milton Keynes, UK). HbA1c was measured at phase 7 on a calibrated HPLC system (4). 
Analysed samples for fasting glucose, 2-h glucose, fasting insulin, 2-h insulin, HOMA-IR, 
HbA1c and CRP were n=3038, n=3036, n=2866, n=3022, n=2199, n=3040 and n=2963, 
respectively, for rs4251961 and n=2992, n=2990, n=2821, n=2976, n=2164, n=2994 and 
n=2917, respectively for rs6759676. 
National FINRISK Study (FINRISK) 
(i) Study population: FINRISK surveys are cross-sectional, population-based studies 
conducted every five years since 1972 to monitor the risk of chronic diseases. For each 
survey, a representative random sample was selected from 25–74 year-old inhabitants of five 
geographical regions in Finland. The survey included a questionnaire and a clinical 
examination, at which a blood sample was drawn, with linkage to national registers of 
cardiovascular and other health outcomes. Study participants were followed up through 31 
December 2010. The current study included eligible individuals from FINRISK surveys 
conducted in 1997 (FINRISK 1997) and in 2007 (Dietary, Lifestyle, and Genetic determinants 
of Obesity and Metabolic syndrome [DILGOM] study collected as an extension to the 
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FINRISK 2007 survey) forming a total sample size of 5004 individuals from whom IL-1RA 
measurements and genotype data were available. 
(ii) IL-1RA measurements: In FINRISK 1997 IL-1RA levels were determined at the 
laboratory of University of Mainz, Germany, from serum samples by ELISA (R&D Systems). 
The intra- and inter-assay CVs were 3.59% and 5.68%, respectively. In FINRISK 
2007/DILGOM, IL-1RA was determined from serum at the laboratory of the Population 
Studies Unit of the National Institute for Health and Welfare, Turku, Finland, using the 
Quantikine ELISA from R&D Systems. The detection limit was 31 pg/ml. Intra- and inter-
assay CVs were 2.2% and 10.3%, respectively. 
(iii) Genotyping and quality control: FINRISK individuals from the year 1997 and a specific 
subset of individuals examined more carefully for metabolic traits in the year 2007 
(FINRISK1997 and DILGOM GWAS, respectively, total n of 1146 available for this study) 
were genotyped in the Sanger Institute (Cambridge, UK) with the Illumina Human 610K 
BeadChip. This set of samples was imputed to the reference panel B36rel22 using the 
software Mach v.1.0.16. In the imputation, filters of <95% for call rate, <1% for MAF and 
<10-6 for HWE P value were used. A subset (n=3858 available for this study) of FINRISK 
2007 individuals (DILGOM metabo) was genotyped using the Illumina Cardiometabochip. To 
control the data quality, sex mismatch and relatedness checks were performed and any 
observed discrepancies were removed from both data sets. For this analysis, the phenotype 
data was filtered for outliers. In the analysis, thresholds of <95% call rate, <10-6 for HWE  P 
value, <1% for MAF, max. 10% for missingness per SNP and max. 10% for missingness per 
individual were applied for the genotyped data.  
(iv) Measurement of metabolic and immunologic traits: Glucose levels in FINRISK 1997 
were measured from serum samples (fasting duration at least four hours) using the glucose 
hexokinase method with the detection range of 0.6-44 mmol/l. The devise used was Olympus 
AU400. Insulin levels were determined from serum with chemiluminescent microparticle 
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immunoassay CMIA (Abbott, Architect i2000) with an intra-assay CV of 3.05% of and an 
inter-assay CV of 3.31%. CRP was determined from serum by latex immunoassay CRP16 
(Abbott, Architect c8000, Abbott Laboratories, Chicago, IL). The intra-assay and inter-assay 
CVs were 0.83% and 0.93%, respectively.  
In the FINRISK 2007/DILGOM survey, glucose was measured from fasting plasma samples 
using the glucose hexokinase method with the reference range of 2.00 (min) to 20.00 (max) 
and a detection limit of 0.14 mmol/l. The devise used was Architect ci8200 (Abbott 
Laboratories, Abbott Park, IL). Insulin was determined from fasting serum with the 
chemiluminescent microparticle immunoassay CMIA (Abbott Laboratories) with mean inter-
assay CVs of 3.4% using the Architect ci8200 (Abbott Laboratories). Serum CRP was 
determined with an immunoturbidimetric method (MULTIGENT CRP Vario, Abbott 
Laboratories) using the Architect ci8200. Mean inter-assay CVs were 3.7%. 
In FINRISK 1997, analyzed samples for fasting glucose, fasting insulin, HOMA-IR and CRP 
were n=382, n=484, n=367 and n=504, respectively, for rs4251961 and n=382, n=484, n=367 
and n=503, respectively, for rs6759676. 
In the FINRISK 2007/DILGOM survey analyzed samples for fasting glucose, fasting insulin, 
HOMA-IR and CRP were n=4396, n=4412, n=4385 and n=4451, respectively, for rs4251961 
and n=4395, n=4411, n=4384 and n=4450, respectively, for rs6759676. 
(v) Gene expression analysis: From the individuals of the DILGOM GWAS sample, the 
whole blood RNA was obtained and hybridized onto Illumina HumanHT-12 BeadChips 
(Illumina, San Diego, CA). In this study, expression data from 507 individuals was analyzed. 
HEALTH 2000 
(i) Study population: Health 2000 is a population-based national survey on the health and 
functional capacity of Finnish individuals (http://www.terveys2000.fi/julkaisut/baseline.pdf). 
A nationally representative sample of 10,000 individuals was drawn of the population aged 18 
years and older. The survey included an interview about medical history, health-related 
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lifestyle habits, and a clinical examination (for individuals of 30 years of age and older) at 
which a blood sample was drawn. Study participants were followed up through 31 December 
2010 and restricted to be aged ≤80 years at baseline. In this study we used the GenMets 
sample which includes individuals with metabolic syndrome and matched controls drawn 
from the Health 2000 study.  A total sample size of 2010 individuals from whom IL-1RA 
measurements and genotype data were available was used. 
(ii) IL-1RA measurements: IL-1RA was determined from nonfasting serum using ELISA 
(R&D Systems, Minneapolis, MN). The intra- and inter-assay coefficients of variation (CVs) 
were 3.59% and 5.68%, respectively. 
(iii) Genotyping and quality control: 2173 individuals from the GenMets cohort have been 
genotyped with the Illumina Human 610 000 BeadChip in Sanger Institute (Cambridge, UK). 
To control the data quality, sex mismatch and relatedness checks were performed and any 
observed discrepancies removed. GenMets has been imputed to the reference panel B36rel22 
using the software Mach v.1.0.16. In the imputation, filters of <95% for call rate, <1% for 
MAF and <10-6 for HWE P value were used. For this analysis, the phenotype data was filtered 
for outliers. Thresholds of 95% call rate and 10-6 for the Hardy-Weinberg equilibrium P value 
for an individual SNP were used. 
(iv) Measurement of metabolic and immunological traits: Glucose levels were measured from 
serum samples (fasting duration at least four hours) using the glucose hexokinase method with 
inter-assay CVs of 2.1% and 2.3% for mean concentrations of 9.3 and 5.2 mmol/l, 
respectively. The devise used was Olympus AU400 (Tokyo, Japan). Insulin levels were 
determined from nonfasting serum with an automated microparticle enzyme immunosorbent 
assay (MEIA) on an Abbot IMX analyzer (Abbott Laboratories) with inter-assay CVs of 4.6% 
and 4.0% for mean concentrations of 118.7 and 1032.7 pmol/l, respectively.  HbA1c was 
determined with an immunoturbidimetric method using the Architect ci8200 (Abbott 
Laboratories). The CVs were 1.8% for HbA1c of 5.1% and 2.0% for HbA1c of 10.8%. CRP 
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was determined from serum using latex immunoassay CRP16 (Abbott Laboratories). The 
intra- and inter-assay CVs were 0.83% and 0.93%, respectively. Analyzed samples for fasting 
glucose, fasting insulin, HOMA-IR, HbA1c and CRP were n=2127, n=2071, n=2070, n=2102 
and n=1878, respectively, for rs4251961 and n=2126, n=2070, n=2069, n=2101 and n=1877, 
respectively for rs6759676. 
MIGen Study 
(i) Study population: 341 individuals from the National FINRISK Study were sampled into a 
specific pair-matched case-control sample of myocardial events (MIGen). In this cohort, the 
individuals whose main diagnosis or cause of death can be specified with 410, I21, I22 codes 
were defined as cases. These analyses included only individuals from the FINRISK 1997 
study. A total sample size of 111 individuals for whom IL-1RA measurements and genotype 
data were available was used. 
(ii) IL-1RA measurements: IL-1RA was measured as described above for FINRISK 1997. 
(iii) Genotyping and quality control: Individuals from the MIGen sample were genotyped 
with the Affymetrix 6.0 platform in the Broad Institute (Cambridge, MA). To control the data 
quality, sex mismatch and relatedness checks were performed and any observed discrepancies 
were removed. MIGen data was imputed to the reference panel HapMap2 using the software 
Mach. In the imputation, filters of <95% for call rate, <1% for MAF and <10-6 for HWE P 
value were used. For this analysis, the phenotype data was filtered for outliers.  
(iv) Measurement of metabolic and immunological traits: All traits were measured as 
described above for FINRISK 1997. Analyzed samples for fasting glucose, fasting insulin, 
HOMA-IR and CRP were n=86, n=109, n=85 and n=110, respectively, for both SNPs 
(rs4251961 and rs6759676). 
KORA F4 Study 
(i) Study population: The KORA F4 study (2006-2008) is a follow-up survey of the 
population-based KORA S4 study (1999-2001). A total sample of 6640 men and women aged 
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25 to 74 years was drawn from the target population in the city of Augsburg (Germany) and 
two adjacent counties. Of all 4261 participants from the KORA S4 study, 3080 also 
participated in the follow-up survey KORA F4. Genotype data were available for a subset of 
1814 individuals in the age range of 32-81 years at the time of the follow-up. 
(ii) IL-1RA measurements: Serum IL-1RA was determined using the Quantikine ELISA kit 
from R&D Systems (Wiesbaden, Germany) with intra- and inter-assay CVs of 2.8% and 
7.0%, respectively. Data from 718 individuals aged 61-82 years were available for this 
analysis. 
(iii) Genotyping and quality control: All samples were genotyped with the Affymetrix Human 
SNP Array 6.0. Hybridization of genomic DNA was done in accordance with the 
manufacturer’s standard recommendations. Genotypes were determined using Birdseed2 
clustering algorithm (Affymetrix Array 6.0). For quality control purposes, we applied a 
positive control and a negative control DNA every 96 samples. On chip level only subjects 
with overall genotyping efficiencies of at least 93% were included. In addition the called sex 
had to agree with the sex in the KORA study database. Imputation of genotypes was 
performed with the software IMPUTE v0.4.2 based on HapMap II. 
(iv) Measurement of metabolic and immunological traits: Blood was collected without stasis 
and blood was kept at 4°C until centrifugation. All blood parameters, except for 2-hour 
glucose and 2-hour insulin, were based on fasting blood samples. Serum samples were stored 
at -80°C until assayed. Serum glucose levels were assessed using the hexokinase method 
(GLU Flex, Dade Behring). Serum insulin was determined by ELISA (Invitrogen, Karlsruhe, 
Germany). HbA1c was measured using the HPLC method. Plasma concentrations of CRP 
were assessed by an immunonephelometric assay on a BN II analyzer (Dade Behring, 
Marburg, Germany). Sample sizes for the analysis of fasting glucose, 2-hr glucose, fasting 
insulin, 2-hr insulin, HOMA-IR, HbA1c and CRP were n=1779, n=1598, n=1776, n=713, 
n=1777, n=723 and n=1777, respectively. 
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(v) Gene expression analysis: Total RNA was extracted from fasting whole-blood samples 
that were taken between 8 a.m. and 11 a.m. RNA was reverse transcribed and biotin-UTP-
labeled into cRNA using the Illumina TotalPrep-96 RNA Amp Kit (Ambion, Darmstadt, 
Germany). Gene expression levels were determined using the Illumina Human HT-12 v3 
Expression BeadChip (Illumina, San Diego, CA). Expression data was log2-transformed and 
normalized by quantile normalization. Data from 718 individuals aged 61-82 years were 
available for this analysis. 
Gutenberg Health Study 
(i) Study population: The Gutenberg Health Study (GHS) is designed as a community-based, 
prospective, observational, single-center cohort study in the Rhine-Main area of Western 
Germany. The sample was drawn randomly from the governmental local registry offices in 
the city of Mainz and the district of Mainz-Bingen. The sample was stratified 1:1 for sex and 
residence (urban and rural) and in equal strata for decades of age. Individuals between 35 and 
74 years of age were enrolled. Exclusion criteria were insufficient knowledge of the German 
language and physical or psychological inability to participate in the examinations at the study 
center. Baseline examination of 15,000 study participants was performed between 2007 and 
2012. Genotype data and IL-1RA levels were available for a subgroup of 4158 individuals. 
(ii) IL-1RA measurements: IL-1RA was determined by ELISA (R&D Systems, Wiesbaden, 
Germany). The inter- and intra-assay CVs were 3.59% and 5.68%, respectively. Data were 
available for this analysis from 2984 and 1174 individuals from GHS I and GHS II, 
respectively. 
(iii) Genotyping and quality control: Genomic DNA was extracted from buffy coats prepared 
from EDTA blood samples. Genotyping was performed using the Affymetrix Genome-Wide 
Human SNP Array 6.0, as described by the Affymetrix user manual. Genotypes were called 
using the Affymetrix Birdseed-V2 calling algorithm and quality control was performed using 
GenABEL (http://mga.bionet.nsc.ru/nlru/GenABEL/). Because genotyping was performed in 
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two successive waves (cohort GHS I (n=3500) and cohort GHS II (n=1500)), the two cohorts 
were analyzed separately. Individuals with a call rate below 97% or an autosomal 
heterozygosity higher than 3 SD around the mean were excluded. After applying standard 
quality criteria (minor allele frequency 1%, genotype call rate 98% and P value of deviation 
from Hardy-Weinberg equilibrium), 662,405 SNPs in 2996 subjects (GHS I) and 673,914 
SNPs in 1179 subjects (GHS II), respectively, remained for analysis. Imputations based on 
HapMap 2 release 24 were performed separately in GHS I and GHS II using IMPUTE v2.1.0. 
In total, 2,588,505 (GHS I)/2,586,553 (GHS II) SNPs with a MAF≥1% were available for 
genetic analyses. 
(iv) Measurement of metabolic and immunological traits: Blood sampling was carried out 
under fasting conditions in lying position. Glucose, insulin, HbA1c and CRP were measured 
immediately after blood withdrawal by routine laboratory measurements. In GHS I and GHS 
II, n=813 and n=1308 individuals, respectively, had a CRP level of <1.0 mg/l which was the 
limit of detection (LOD). These values were set to 0.5 mg/l (LOD/2). Sample sizes for the 
analysis of fasting glucose, HbA1c and CRP were n=2183, n=2969 and n=2983, respectively, 
in GHS I and n=880, n=1179 and n=1179, respectively, in GHS II. 
(v) Gene expression analysis: Gene expression analysis was performed using the Illumina 
HumanHT-12 v3 BeadChip using total monocytic RNA. The integrity of the total RNA was 
assessed through analysis on an Agilent Bioanalyzer 2100 (Agilent Technologies, Böblingen, 
Germany). Reverse transcription and cRNA synthesis were performed using the Illumina 
TotalPrep-96 RNA Amplification Kit (Ambion, Darmstadt, Germany). Data from 1133 
individuals were available for this analysis. 
Young Finns Study (YFS) 
(i) Study population: The Cardiovascular Risk in Young Finns is a population-based 27-year 
follow-up study (http://med.utu.fi/cardio/youngfinnsstudy/). The first cross-sectional survey 
was conducted in 1980, when 3596 Caucasian subjects aged 3-18 years participated in the 
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study. In adulthood, the latest 27-year follow-up study was conducted in 2007 to 2204 
participants aged 30-45 years. For 1998 individuals who had participated in the study in 2007 
genotype data and IL-1RA measurements were available for this analysis. 
(ii) IL-1RA measurements: A magnetic bead-based multiplex assay was used to determine the 
concentration of IL-1RA in blood. 20 µl aliquots of serum samples (stored at -70 ºC and never 
thawed before) from 2200 persons were analyzed using Bio-Plex Pro Assays (27-Plex kit 
including IL-1RA). Intra- and inter-assay CVs were 9.62% and 10.86%, respectively. Lower 
limit of detection was 10.85 pg/ml.  
(iii) Genotyping and quality control: Genotyping of YFS samples was performed at the 
Sanger Institute (Cambridge, UK) using the custom-built Illumina BeadChip Human670K 
array. Genotypes were called using Illumina’s clustering algorithm.  Following quality control 
filters were applied to the data: MAF 0.01, maximum per-SNP missing 0.05, maximum per-
person missing 0.05, and HWE P value of 10-6. In addition, sex mismatch and relatedness 
checks were performed and any observed discrepancies removed. YFS has been imputed to 
the HapMap2 reference panel using the software Mach v.1.0 
(http://www.sph.umich.edu/csg/abecasis/MACH/). For this analysis, the phenotype data was 
filtered for outliers. Thresholds of 95% call rate and 10-6 for Hardy-Weinberg equilibrium P 
value for an individual SNP were used. 
(iv) Measurement of metabolic and immunological traits: Fasting serum glucose 
concentration was determined by the enzymatic hexokinase method (Glucose reagent, 
Olympus AU400, Olympus, Center Valley, PA). Fasting serum insulin concentration was 
determined by a microparticle enzyme immunoassay (IMx insulin reagent, Abbott 
Diagnostics) on an IMx instrument (Abbott). Serum CRP was analyzed using an automated 
analyzer (Olympus AU400) and a highly sensitive turbidimetric immunoassay kit (CRP-UL-
assay, Wako Chemicals, Neuss, Germany). The detection limit was 0.02 mg/l. Inter-assay 
CVs were 3.33% at the mean level of 1.52 mg/l (n=116) and 2.65% at the mean level of 2.51 
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mg/l (n=168). Analyzed samples for fasting glucose, fasting insulin, HOMA-IR and CRP 
were n=1951, n=1946, n=1938 and n=1952, respectively, for rs4251961 and n=1950, n=1945, 
n=1937 and n=1951, respectively for rs6759676. 
 
Statistical analysis. For the discovery cohorts, separate within-cohort linear regression 
analyses were performed to assess associations between SNPs and systemic IL-1RA levels 
using an additive genetic model adjusting for age, sex, BMI, waist-hip ratio, smoking (current 
vs. never/ex smokers) as well as ancestry principal components and field center, as needed. 
After verifying strand alignment, an inverse variance-weighted fixed effects meta-analysis of 
the results from the seven studies was conducted. I2 estimates were used to assess study 
heterogeneity. Since five of our seven datasets used genome-wide platforms we adopted 
discovery a P-value threshold of p<5.0x10-8, in keeping with that generally used in genome-
wide association studies. Although five of the studies also used imputed data, the genome-
wide significance level of p<5.0x10-8 for the number of independent tests was still applicable 
since imputed SNPs were in linkage disequilibrium (LD) with genotyped SNPs.  
Conditional analysis. To explore whether the signals at each locus were independently 
associated with the phenotype of interest (IL-1RA), we carried out a conditional analysis, 
where the most significantly associated SNP from the meta-analysis was added to the within-
study linear regression model as a covariate, followed by meta-analysis of the resulting 
conditional estimates. If any SNPs remained significant at the discovery P value threshold, the 
top SNP was again added to the model as covariate. This process was repeated until no more 
SNPs passed the discovery P value threshold.  
Replication analysis. The SNPs identified as independent signals in the conditional analysis 
were then taken forward for replication. In the replication cohorts the same methodological 
approach was used to obtain an effect estimate for these SNPs as in the discovery cohorts. As 
study heterogeneity was observed, the summary estimates obtained from all replication 
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studies were meta-analyzed using a random-effect model. We excluded one study (Young 
Finns Study (YFS)) from the main analysis for IL-1RA, because a different laboratory method 
was used to determine IL-1RA levels (bead-based multiplex assay instead of the ELISA 
method used in all other studies).  
The proportion of the variance in IL-1RA explained by rs4251961 and rs6759676 was 
calculated in the independent population cohort FINRISK1997 (no sample overlap with the 
discovery cohorts). More recent genotype data in the FINRISK1997 cohort (core-exome chip 
from Illumina) was imputed using the 1000 Genomes March 2012 release using the IMPUTE 
software. Imputation information for rs4251961 was 0.97 and for rs6759676 was 0.997. The 
proportion of variance explained by the two SNPs together was tested with residuals from 
age, sex, BMI, waist-hip ratio and smoking adjusted ln-transformed IL-1RA levels using 
linear model: residuals ~ rs4251961 + rs6759676. 
Association with metabolic traits. To determine if the independent SNPs associated with IL-
1RA levels were also associated with metabolic and immunological traits we examined the 
association of these SNPs with fasting and 2-hr glucose and insulin, HbA1c, HOMA-IR and 
CRP levels in all discovery and replication studies where each phenotype was available. 
Within-study linear regression analysis was carried out for each SNP, adjusting for age and 
sex in a first model and additionally for BMI, waist-hip ratio, smoking (current vs. never/ex-
smokers) as well as ancestry principal components and field centre as needed. Summary 
estimates obtained from all studies were meta-analyzed using a fixed-effect model, as before, 
with I2 estimates used to assess study heterogeneity. 
In silico functional analysis. To investigate whether any SNPs could potentially have a 
functional effect we checked whether each associating SNP were located in any of the 
ENCODE regulatory regions (31).  
Gene expression analysis in blood. Furthermore, the association of the two replicated SNPs 
with gene expression levels was analyzed in three cohorts (DILGOM GWAS, KORA and 
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Gutenberg Health Study) for which transcriptomics data were available. In these cohorts, the 
within-cohort linear regression analyses were performed for each SNP with adjustment for 
age, sex, BMI and waist-hip ratio and smoking when the data were available. Technical 
variables were also used for adjustment in KORA and Gutenberg Health Study, as described 
previously (32). 
Analysis of publicly available eQTL data. We used the Genevar software, which allows an 
integrative analysis and visualization of SNP-gene associations in expression quantitative trait 
loci (eQTL) studies. We queried eQTL data from adipose tissue collected from 856 healthy 
female twins (one-third monozygotic and two-thirds dizygotic from the TwinsUK adult 
registry) of the Multiple Tissue Human Expression Resource (MuTHER) (33). In this study, 
expression profiling of the samples was performed using Illumina Human HT-12 V3 
BeadChips (Illumina), while genotyping was performed with a combination of Illumina 
HumanHap300, HumanHap610Q, 1M-Duo and 1.2MDuo 1M chips (33). We queried the 
dataset for any eQTL associations with rs4251961 and rs6759676. 
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RESULTS 
 
Association between SNPs and circulating IL-1RA 
Table 1 provides the characteristics of all discovery and replication cohorts. In the discovery 
analysis, 54 SNPs passed the discovery P value threshold of 5.0x10-8 (adjusted for age, sex, 
BMI, waist-hip ratio and smoking; Figure 1A, Supplementary Table 1). All these SNPs reside 
within the same region on chromosome 2 spanning the IL1F10 and IL1RN genes.  
Two SNPs remained significant at the discovery threshold after a first conditional analysis on 
the most significant SNP, rs4251961. The most significant SNP in the conditional analysis 
was rs6759676 with P= 1.5x10-10. When the meta-analysis in the discovery cohorts was 
repeated with both SNPs rs4251961 and rs6759676 as covariates, no additional SNPs 
remained significant at the discovery P-value threshold. Therefore, these 2 SNPs were 
considered to be the only robust, independent signals in the chromosome 2 region and were 
taken forward for replication (Figures 1B and 1C). The proportion of the variance in IL-1RA 
explained by rs4251961 and rs6759676 together was 2.0%.   
Both SNPs were also clearly associated with IL-1RA levels in the replication cohorts, with the 
combined association P<0.05 (Table 2). Results of the meta-analyses including the YFS data 
are given in Supplementary Table 2. 
In silico analysis of rs6759676 and rs4251961 
The rs6759676 SNP is in strong LD with rs6761276 (R2=0.9; based on 1000 Genome CEU 
population). The latter is a non-synonymous coding SNP within the IL1F10 gene, which has 
been previously reported to be associated with IL-1RA (25). However, PolyPhen-2 (34) 
predicts this SNP to be ‘benign’ with no effect on protein structure/function. Based on 
ENCODE data rs6759676 falls within a region enriched for the H3K27Ac histone acetylation 
mark (often found near active regulatory elements) in epidermal keratinocytes and human 
mammary epithelial cells; within a DNase hypersensitive region (characteristic of open 
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chromatin regions) in multiple cell lines; and also within STAT transcription factor binding 
sites (Supplementary Figure 1). This suggests that the rs6759676 SNP could influence 
expression of nearby genes. 
The rs4251961 SNP upstream (5’) of the IL1RN gene also falls within a region enriched for 
the H3K27Ac histone acetylation mark in epidermal keratinocytes cells and human mammary 
epithelial cells (Supplementary Figure 2). It is in close proximity to regions enriched for 
transcription factor binding sites and indicative of open chromatin, suggesting that variants in 
this region could affect gene expression of IL1RN (Supplementary Figure 2). 
Association between significant SNPs, immunological and glycemic traits 
The minor allele of rs4251961 was inversely associated with circulating IL-1RA 
concentrations, whereas a positive association was observed for rs6759676 (Table 3, Figures 
2A, 2B). The IL-1RA-decreasing alleles were also significantly associated with higher CRP 
levels for both SNPs (Figures 2C, 2D). These analyses were adjusted for age, sex, BMI, 
waist-hip ratio and smoking. 
While no associations were found between rs4251961 and fasting glucose, 2-hr glucose, 
fasting insulin, 2-hr insulin and HOMA-IR, the IL-1RA-increasing allele of rs6759676 was 
associated with lower fasting insulin (P=0.010) and lower HOMA-IR (P=0.006) (Figures 2E-
2H). These associations were nominally significant, but became non-significant after 
Bonferroni adjustment for multiple testing. 
Association between significant SNPs and expression of IL-1 family genes in/near the IL-
1RN locus 
Associations between rs4251961, rs6759676 and transcript levels were first assessed for 
IL1RN/IL-1RA. We found no associations for either SNP with IL-1RA mRNA levels in 
peripheral blood in the KORA F4 Study (N=718, Table 4). In line with this finding, no 
associations were found in the Gutenberg Health Study (GHS I, N=1133) for either SNP 
(P=0.58 and P=0.89 for transcript ILMN_1774874, respectively) in isolated monocytes.  
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In KORA, we also assessed the potential impact of rs4251961 and rs6759676 on the 
expression of additional genes of the IL-1 family near the IL1RN locus in order to exclude 
pleiotropic effects beyond IL-1RN/IL-1RA (Table 4). Data were available for IL1A, IL1B, 
IL1F7/IL37, IL1F9/IL36G, IL1F6/IL36A, IL1F8/IL36B, IL1F5/IL36RN and IL1F10 from 723 
participants of the KORA F4 study. After adjustment for age, sex, BMI, waist-hip ratio, 
smoking and technical variables, we found a nominally significant association between 
rs4251961 and one transcript of IL1F8/IL36B (P=0.03) and another nominally significant 
association between rs6759676 and one transcript of IL1F7/IL37 (P=0.04). However, these 
associations were not statistically significant after adjusting for multiple testing. 
In the DILGOM GWAS sample (N=507), the eQTL analysis for rs4251961 and rs6759676 
adjusted for age, sex, BMI and WHR showed no association with IL-1RA mRNA expression 
level (IL1RN) after Bonferroni correction for multiple testing leading to a significance level of 
P=4.6x10-4. When testing the association of our variants with the expression loci located 
within 1 Mb with the IL1RN locus used as a midpoint, a significant association of rs4251961 
with the expression of the gene SLC20A1 (solute carrier family 20 (phosphate)) was observed 
(P=2.4x10-4). Moreover, rs6759676 was significantly associated (P=9.8x10-6) with the 
expression of PAX8 (paired box 8). 
Analysis of publicly available eQTL data 
Grundberg et al. (33) used a per-tissue false discovery rate (FDR) of 1% to identify cis-
eQTLs, corresponding to P<5.0×10−5 in adipose tissue, and a GWAS threshold of P<5x10-8 
for trans-eQTLs. Although rs6759676 showed nominal association (0.0001<P<0.001) with 
two probes (ILMN_1774874 and ILMN_1689734) of the IL1RN gene, none of those 
associations passed the specified significance thresholds for the 2 SNPs. 
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DISCUSSION 
 
Our study presents four key findings regarding genetic determinants of circulating IL-1RA 
concentration and their associations with gene expression levels, metabolic and 
immunological variables associated with cardiometabolic disease risk: First, two independent 
SNPs in the IL1RN and IL1F10 loci (rs4251961 and rs6759676) were significantly associated 
with IL-1RA levels. Second, these associations were independent of associations of the SNPs 
with gene expression of IL-1RA or other IL-1 family members in whole blood or monocytes. 
Third, alleles of both SNPs which were associated with elevated IL-1RA were associated with 
lower circulating CRP concentration. Fourth, the IL-1RA-raising and CRP-lowering allele of 
rs6759676 was also associated with lower fasting insulin and lower HOMA-IR.   
 
Genetic determinants of circulating IL-1RA 
Previous studies reported significant associations between several SNPs in or near the IL1RN 
locus and circulating IL-1RA (24,29), but it was not clear whether these represented 
independent associations. Our study shows for the first time that at least two independent 
genetic determinants of circulating IL-1RA are located in the vicinity of this locus. The first is 
marked by rs4251961 and has been described previously in European and African American 
ancestry populations (24,29,35). Most published SNPs that were previously reported to be 
associated with IL-1RA are in LD with rs4251961 (r² 0.4-0.7, assessed with SNAP version 
2.2, http://www.broadinstitute.org/mpg/snap/ldsearchpw.php). The second genetic region 
marked by rs6759676 in the IL1F10 locus appears to represent a novel independent effect 
which does not correlate with rs4251961 (r²=0.106), but shows some correlation to the 
recently described rs6743376 (30).  
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Associations between gene variants within or near the IL1RN locus have been reported with 
fat mass (23,27). However, our observations were independent of indices of obesity as the 
analyses were adjusted for body mass index and waist-hip ratio.   
 
Associations between rs4251961, rs6759676 and gene expression 
The most probable mechanism linking both SNPs with circulating IL-1RA levels would be 
the regulation of IL1RN transcription. Accordingly, our in silico analysis suggested that both 
SNPs may regulate gene expression because of the density of transcription factor binding sites 
in their vicinity. However, this was not confirmed in our directly observed analyses of whole 
blood or monocytes, as neither rs4251961 nor rs6759676 had any substantial impact on 
expression levels of IL1RN. The analysis of publicly available eQTL data indicated, however, 
that such an effect cannot be ruled out for rs6759676 in adipose tissue (33), and effects on 
transcription may be possible in other IL-1RA-producing cell types and tissues. In this context 
it is notable that one study reported an association between rs4251961 and several other SNPs 
with the peptidoglycan-induced production of the IL-1RA protein in whole-blood samples 
(26) suggesting a potential role for this SNP in the regulation of IL-1RA in response to 
inflammatory stimuli.  
To examine pleiotropic effects of both SNPs we also assessed their associations with gene 
expression levels of other IL-1 family members encoded near the IL1RN locus, because an 
indirect effect via the regulation of the expression of IL-1β with subsequent upregulation of 
IL-1RA is conceivable. However, we found no convincing evidence for such an indirect 
effect.  
Overall, our results are consistent with the regulation of circulating IL-1RA by post-
transcriptional mechanisms influenced by genotype at rs4251961 and rs6759676. However 
the possibility that both SNPs could be linked with gene expression levels in tissues other 
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than whole blood cannot be excluded based on our work and needs to be explored in future 
studies. 
 
Associations between rs4251961, rs6759676 and C-reactive protein levels 
Given the anti-inflammatory properties of IL-1RA, it is possible that genetically determined 
levels of IL-1RA are associated with other markers of subclinical inflammation. The most 
frequently measured such marker is CRP, which we also included in our study. As for 
circulating IL-1RA, our findings of associations of two independent SNPs with systemic CRP 
levels are novel and extend the current literature because previous reports focused only on 
rs4251961 (26) or identified rs6734238 in the IL1F10 locus, which is in LD with rs4251961 
(r2=0.613; r2<0.1 with rs6759676), as a determinant of CRP levels in a GWAS (36). The 
association between rs6734238 in IL1F10 and CRP was confirmed at genome-wide 
significance in African American women, but not in Hispanic American women (37). The 
associations between rs6759676 and CRP concentration has not been previously described. 
Notably, our observation that IL-1RA-raising alleles of both SNPs were associated with lower 
circulating CRP levels is in line with the aforementioned randomized clinical trial, in which 
treatment with recombinant IL-1RA not only improved glycemic control and beta-cell 
function in patients with T2D, but also decreased systemic CRP levels (6). 
Taken together, these data indicate that even modest genetically determined elevations of 
circulating IL-1RA throughout life counteract systemic subclinical inflammation as reflected 
by circulating CRP. Further work should investigate the association of IL-1RA-associated 
variants and a wider range of inflammatory markers to corroborate this conclusion. For 
example, we have previously reported an association of rs425196 with IL-6 (38). This is of 
interest as recent Mendelian randomization analyses suggest that IL-6 signalling is causally 
associated with cardiovascular disease (39).   
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Associations between rs4251961, rs6759676 and parameters of glucose metabolism 
If subclinical inflammation, and higher IL-1β in particular, are causally related to the 
development of T2D, the genetic upregulation of IL-1RA should be associated with more 
favorable metabolic control. Associations between SNPs in/near the IL1RN locus and 
parameters of glucose metabolism have been investigated before. However evidence from 
studies smaller than our meta-analysis report no significant associations between rs4251961 
and 6 other SNPs not in LD with either of our strongest signals with and fasting glucose or 
fasting insulin (24,28). A third study reported an association between rs3213448 (r2 with 
rs4251961 and rs6759676 <0.1) and incident T2D in men (but not in women) in HEALTH 
2000, but no association in FINRISK97 (12). 
Our study represents the largest study to date to investigate associations between genetic 
determinants of IL-1RA and measures of glucose metabolism. We observed that the IL-1RA-
increasing allele of rs6759676 is associated with lower fasting insulin, and HOMA-IR, thus 
indicating that this SNP is associated with higher insulin sensitivity. However, we found this 
association only for rs6759676, whereas it was not statistically significant for rs4251961, 
although the associations between both SNPs and circulating IL-1RA were comparable. In 
order to explain this difference, gene expression data from other insulin-responsive tissues 
would be desirable to investigate whether both SNPs act mainly via the regulation of IL-1RA 
levels or whether one of them or even both also have pleiotropic effects by regulating other 
IL-1 family members that could represent mediators of the relationship between genetic 
variation, immunological and metabolic effects. 
Our findings with genetic data mirror those from an intervention study. A recent clinical trial 
showed that daily subcutaneous injections of recombinant IL-1RA (which raised circulating 
IL-1RA levels) reduced HbA1c levels in patients with T2D (6), although it was not clear to 
what extent IL-1RA acted on insulin sensitivity or beta-cell function. Our findings are 
biologically plausible because the only known function of IL-1RA in humans is to block IL-
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1β-mediated signalling. Importantly, this anti-inflammatory effect has pleiotropic metabolic 
consequences because IL-1β interferes with insulin signalling in adipocytes and hepatocytes 
and also suppresses insulin-induced glucose uptake, inhibits lipogenesis and decreases the 
release of adiponectin from adipocytes (40-42).  
Our findings appear not to be in agreement with previous observational data from the 
Whitehall II study and Finnish cohort studies which suggest that an upregulation of IL-1RA in 
the circulation was linked to an increased risk of T2D (9-12). We hypothesize that the 
upregulation of IL-1RA before the clinical manifestation of T2D represents a 
counterregulation to proinflammatory and/or metabolic stimuli and can mainly be interpreted 
as a futile response to the presence of multiple diabetes risk factors which does not confer a 
sufficient degree of protection against the onset of the disease.  
In the present study, our findings reflect the impact of a genetically determined and lifelong 
upregulation of IL-1RA without effects of potentially confounding factors on the association 
between genotype and metabolic traits. The data indicate that the persistent genetically 
determined upregulation of IL-1RA may attenuate diabetes-promoting effects of IL-1β and 
thus support the notion that subclinical inflammation and insulin resistance are causally 
related. However, our data have to be interpreted with caution because we observed 
significant effects for only one of the two IL-1RA-related SNPs, and our findings were only 
nominally significant. 
 
Strengths and limitations 
Our study has several strengths: it is the largest study so far to search for genetic determinants 
of IL-1RA levels and their immunological and pleiotropic effects; and the genetic approach of 
the potential causal impact of IL-1RA levels on metabolic traits is more robust against 
confounding than observational studies based on circulating IL-1RA only. However, our 
analyses were limited in scope by gene-centric genotyping platforms in some cohorts. 
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Therefore, the existence of further genetic determinants of IL-1RA levels with comparable 
effect sizes cannot be ruled out. We had only data for HOMA-IR as surrogate measure of 
insulin resistance, and dynamic measures of beta-cell function were not available in our 
analysis. Finally, we observed differences between studies with IL-1RA measured by ELISA 
and one study that measured IL-1RA with a bead-based multiplex assay, which led to the 
exclusion of this latter study from the main analysis. Unfortunately, we were not able to 
perform comparisons of different laboratory methods for IL-1RA measurement to further 
elucidate the underlying reasons for this observation. 
 
Conclusions 
Taken together, we identified one novel genetic determinant of circulating IL-1RA levels in 
the IL1F10 locus which exerts systemic anti-inflammatory effects. Furthermore, we provide 
preliminary evidence that genetically raised IL-1RA concentrations by this SNP may protect 
against the development of insulin resistance. Thus, our data are in line with modest 
therapeutic benefits reported for novel IL-1β-targeting treatment strategies.  
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TABLE1. Cohort characteristics 
 
  
Discovery Cohorts Replication Cohorts 
   WHII FR1997 
DILGOM 
(FR07) 
GWAS 
DILGOM 
(FR07) 
metabochip 
HEALTH2000 
GenMets 
cases 
HEALTH2000 
GenMets 
controls 
FIN 
MIGen 
KORA GHS1 GHS2 YFS 
N 2160 468 678 3858 979  1031 111 719 2984 1174 1998 
Age (years) 48.9 (6.0) 56.1 (12.5) 
53.5 (13.4) 
52.4 (13.5) 51.4 (11.1) 49.9 (10.9) 
 56.1 
(8.8) 
60.9 (8.9) 55.9 (10.9) 55.1 (10.9) 37.7 (5.0) 
Sex (% males) 77.1 47.6 48.8 45.9 50.5 47.1 62.2 48.65 51.4 50.1 45.2 
BMI (kg/m²) 25.4 (3.7) 26.5 (4.3) 26.6 (4.5) 26.9 (4.7) 29.5 (4.2) 25.1 (3.5) 
 28.1 
(4.7) 
28.14 (4.78) 27.1 (4.7) 27.3 (5.0)  26.0 (4.8) 
Waist-hip ratio 0.9 (0.08) 0.9 (0.09) 0.9 (0.09) 0.9 (0.09) 0.9 (0.08) 0.9 (0.08) 
0.9 
(0.09) 
0.89 (0.08) 0.93 (0.09) 0.92 (0.1)  0.9 (0.09) 
Current smokers 
(%) 
12.2 27.1 18.9 17.1 28.8 30.2 21.6 14.53 18.2 21.2 27.2 
Fasting glucose 
(mmol/l) 
5.3 (0.5) 5.07 (0.64)   5.90 (0.72)  5.87 (0.72) 5.51 (0.50)  5.22 (0.42)  
5.20 
(0.86)  
5.60 (1.10) 5.29 (1.05) 5.26 (0.85) 5.29 (0.56)  
2-hr glucose 
(mmol/l) 
5.6 (1.7) NA NA  NA  NA NA NA 6.56 (2.21) NA NA NA 
Fasting insulin 
(µU/ml) 
6.5 (5.7) 6.73 (4.17)   7.24 (8.30)  6.73 (5.09) 10.85 (6.13)  5.98 (2.96)  
 7.90 
(4.76) 
8.83 (24.31) NA NA 8.66 (6.67)  
2-hr insulin 
(µU/ml) 
46.5 (39.1) NA NA  NA  NA NA NA 71.64 (79.22) NA NA NA 
HOMA-IR 0.9 (0.58) 1.51 (1.04)  1.92 (2.46)  1.80 (1.57)   2.67 (1.58) 1.41 (0.74)  
1.85 
(1.19)  
2.33 (6.45) NA NA  2.09 (1.80) 
HbA1c (%) 5.3 (0.7) NA NA NA 5.32 (0.33)   5.13 (0.31) NA 5.74 (0.68) 5.47 (0.74) 5.48 (0.67) NA 
HbA1c 
(mmol/mol) 
34 (7.7) NA NA NA 35 (3.6) 33 (3.4) NA 39 (7.4) 36 (8.1) 36 (7.3) NA 
CRP (mg/l) 1.5 (1.8) 2.65 (3.77)   2.14 (3.07)  2.03 (2.78) 2.42 (3.62)  1.63 (2.77)  
 2.94 
(4.19) 
2.48 (5.08) 2.88 (4.63) 2.86 (4.95)  1.63 (2.32) 
IL-1RA (pg/ml) 286.3 (205.3) 
251.4 
(149.0) 
 291.6 
(146.0) 
312.3 (161.8) 433.9 (247.3) 323.4 (169.8) 
295.0 
(154.4) 
335.03 
(160.51) 
353.5 (189.1) 
392.4 
(210.2) 
256.7 
(141.0) 
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Genotyping 
platform 
Metabochip 
50k 
cardiochip 
Illumina 
Human 
610K 
BeadChip 
Illumina 
Human 610K 
BeadChip 
Metabochip 
Illumina 
Human 610K 
BeadChip 
Illumina 
Human 610K 
BeadChip 
Affymetr
ix 6.0 
platform 
Affymetrix 
Human SNP 
Array 6.0 
Affymetrix 
Human SNP 
Array 6.0 
Affymetrix 
Human 
SNP Array 
6.0 
Illumina 
BeadChip 
Human670
K array 
 
 
 
For all variables, mean (SD) or % is shown. The number of study participants refers to the individuals for whom genotype data and IL-1RA measurements were 
available. Sample sizes may vary for the other traits as described in the section Research design and Methods. 
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TABLE 2. Meta-analysis results for the SNPs independently associated with circulating IL-1RA levels.  
 
 
 
 
Marker name 
   Chr   Position (HG18) Gene 
Minor 
(coded) 
allele 
Major 
allele Mean MAF 
Discovery 
N Effect SE P I
2
 (%) 
Meta-analysis 
model 
rs4251961 2 113590938 IL1RN C T 0.32 9092 -0.078 0.006 2.19E-34 39.8  FE 
rs6759676 2 113552819 closest IL1F10 C T 0.44 9131 0.063 0.006 6.12E-27 0.0  FE 
Marker name Chr Position (HG18) Gene 
Minor 
(coded) 
allele 
Major 
allele Mean MAF 
Replication  
N Effect SE P I
2
 (%) 
Meta-analysis 
model 
rs4251961 2 113590938 IL1RN C T 0.32 4863 -0.086 0.023 2.00E-04 78.90 RE 
rs6759676 2 113552819 closest IL1F10 C T 0.44 4863 0.099 0.019 3.54E-07 71.91 RE 
Marker name Chr Position (HG18) Gene 
Minor 
(coded) 
allele 
Major 
allele Mean MAF 
Combined 
N Effect SE P I
2
 (%) 
Meta-analysis 
model 
rs4251961 2 113590938 IL1RN C T 0.32 13955 -0.082 0.009 2.76E-21 53.84 RE 
rs6759676 2 113552819 closest IL1F10 C T 0.44 13994 0.075 0.009 1.73E-17 60.45 RE 
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TABLE 3. Association of rs4251961and rs6759676 with quantitative immunological and glycaemic traits.  
 
 
SNP Trait* beta SE P Number of 
studies 
N I
2
 (%) 
rs4251961 IL-1RA (pg/ml) -0.082 0.009 2.76e-21 10 13955 53.84 
 CRP (mg/l) 0.0601 0.0108 2.95e-08 11 17797 0.79 
 Fasting glucose (mmol/l) 0.0005 0.0012 0.6960 11 16822 0.0 
 2-hr glucose (mmol/l) -0.0068 0.0060 0.2637 2 4634 0.0 
 HbA1c (%) 0.0011 0.0013 0.3964 6 10013 0.0 
 Fasting insulin (µU/ml) 0.0099 0.0067 0.1390 9 13664 0.0 
 2-hr insulin (µU/ml) -0.0129 0.0186 0.4881 2 3735 0.0 
 HOMA-IR 0.0071 0.0068 0.2992 9 12821 0.0 
rs6759676 IL-1RA (pg/ml) 0.075 0.009 1.73E-17 10 13994 60.45 
 CRP (mg/l) -0.0284 0.0103 0.0055 11 17747 0.0 
 Fasting glucose (mmol/l) -0.0012 0.0011 0.2603 11 16773 12.5 
 2-hr glucose (mmol/l) 0.0039 0.0060 0.5140 2 4588 0.0 
 HbA1c (%) -0.0007 0.0012 0.5295 6 9966 0.0 
 Fasting insulin (µU/ml) -0.0159 0.0061 0.0096 9 13616 20.2 
 2-hr insulin (µU/ml) -0.0271 0.0182 0.1381 2 3689 0.0 
 HOMA-IR -0.0173 0.0063 0.0063 9 12783 0.0 
 
 
*All traits were ln-transformed. Analyses were adjusted for age, sex, BMI, WHR and smoking (additive model, major allele as reference).  
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TABLE 4. Associations between rs4251961, rs6759676 and mRNA expression of further 
transcripts of the IL-1 family near the IL1RN locus in the KORA F4 Study (N = 718) 
Transcript Gene  Beta SE  P  
rs4251961     
ILMN_1806249   IL1RN 0.0012 0.0085 0.9989 
ILMN_1689734 IL1RN -0.0278 0.0300 0.3527 
ILMN_1774874 IL1RN -0.0063 0.0244 0.7974 
ILMN_1658483 IL1A -0.0020 0.0070 0.7727 
ILMN_1775501 IL1B -0.0099 0.0261 0.7045 
ILMN_2353936 IL37 -0.0064 0.0079 0.4179 
ILMN_1718275 IL37 0.0033 0.0074 0.6518 
ILMN_1697710 IL37 0.0012 0.0185 0.9464 
ILMN_2158713 IL36G -0.0045 0.0070 0.5234 
ILMN_1704000 IL36A 0.0088 0.0075 0.2404 
ILMN_1761927 IL36B 0.0026 0.0068 0.7009 
ILMN_1754002 IL36B 0.0018 0.0075 0.8119 
ILMN_1799519 IL36B 0.0155 0.0070 0.0269 
ILMN_1759141 IL36RN 0.0077 0.0075 0.3015 
ILMN_1804901 IL36RN 0.0123 0.0106 0.2434 
ILMN_1790556 IL1F10 -0.0023 0.0071 0.7507 
ILMN_2359733 IL1F10 -0.0068 0.0074 0.3547 
rs6759676     
ILMN_1806249   IL1RN -0.0144 0.0084 0.0869 
ILMN_1689734 IL1RN 0.0217 0.0296 0.4627 
ILMN_1774874 IL1RN 0.0117 0.0242 0.6292 
ILMN_1658483 IL1A -0.0031 0.0069 0.6579 
ILMN_1775501 IL1B -0.0037 0.0257 0.8851 
ILMN_2353936 IL37 0.0151 0.0078 0.0523 
ILMN_1718275 IL37 -0.0146 0.0073 0.0448 
ILMN_1697710 IL37 0.0291 0.0182 0.1107 
ILMN_2158713 IL36G -0.0110 0.0069 0.1120 
ILMN_1704000 IL36A -0.0035 0.0074 0.6340 
ILMN_1761927 IL36B -0.0043 0.0067 0.5207 
ILMN_1754002 IL36B -0.0093 0.0074 0.2067 
ILMN_1799519 IL36B -0.0101 0.0069 0.1480 
ILMN_1759141 IL36RN -0.0068 0.0074 0.3593 
ILMN_1804901 IL36RN -0.0121 0.0105 0.2466 
ILMN_1790556 IL1F10 0.0020 0.0071 0.7777 
ILMN_2359733 IL1F10 0.0019 0.0073 0.7992 
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Analyses were adjusted for age, sex, BMI, WHR, smoking and technical variables. The first 
column gives Illumina transcript IDs. Alternative nomenclature: IL36RN = IL1F5, IL36A = 
IL1F6, IL37 = IL1F7, IL36B = IL1F8, IL36G = IL1F9. Nominally significant associations are 
highlighted by bold print. 
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Fig. 1. Association between rs4251961, rs6759676 and IL-1RA in the discovery analysis. 
 
Figure 1 shows GWA P values for all the variants that were tested in IL-1RA association 
analysis and that were located in the IL1RN gene cluster on the chromosome 2. A. 
Rs4251961 shows the strongest association with IL-1RA in the discovery analysis. B.  
Rs4251961 remains as an independent hit when conditioning on rs6759676. C. Rs6759676 
remains as an independent hit when conditioning on rs4251961. 
 
 
 
Fig. 2.  Association of rs4251961 and rs6759676 with circulating IL-1RA levels, CRP, 
insulin and HOMA-IR in individual studies included in the discovery and replication 
analysis.  
 
A, B: IL-1RA; C, D: CRP; E, F: insulin; G, H: HOMA-IR. 
All analyses were adjusted for age, sex, BMI, waist-to-hip ratio and smoking. 
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Supplementary Table 1. Meta-analysis results for SNPs associated with IL-1RA in the discovery cohorts. 
 
MarkerName Chr Position (HG18) Gene 
Minor 
(Coded) 
Allele 
Major 
Allele 
Mean MAF 
Discovery 
N Effect SE P 
rs4251961 2 113590938 IL1RN C T 0.32 9092 -0.078 0.006 2.19E-34 
rs6759676 2 113552819 closest IL1F10 C T 0.44 9131 0.063 0.006 6.12E-27 
rs10186133 2 113553415 closest IL1F10 G T 0.42 9126 0.060 0.006 4.52E-24 
rs315949 2 113609245 closest IL1RN A G 0.37 5306 -0.070 0.008 2.80E-19 
rs6731551 2 113561024 closest IL1F10 C T 0.47 9133 -0.052 0.006 1.20E-18 
rs10199363 2 113557262 closest IL1F10 G A 0.18 9134 0.065 0.008 1.31E-16 
rs315921 2 113588522 closest IL1RN A G 0.17 9096 0.065 0.008 4.89E-16 
rs6761276 2 113548783 IL1F10 T C 0.43 5310 0.061 0.008 1.13E-15 
rs315920 2 113589489 closest IL1RN T C 0.19 9095 0.059 0.008 1.26E-14 
rs10176274 2 113557046 closest IL1F10 G C 0.34 3209 -0.085 0.012 6.37E-13 
rs10188292 2 113556914 closest IL1F10 T A 0.34 3209 -0.085 0.012 6.37E-13 
rs6743171 2 113556529 closest IL1F10 C G 0.34 3209 -0.085 0.012 6.37E-13 
rs13398728 2 113558977 closest IL1F10 C T 0.34 3209 -0.085 0.012 6.37E-13 
rs13410964 2 113559754 closest IL1F10 A G 0.34 3209 -0.085 0.012 6.37E-13 
rs6722922 2 113557986 closest IL1F10 T C 0.34 3209 -0.085 0.012 6.37E-13 
rs6750559 2 113558003 closest IL1F10 A G 0.34 3209 -0.085 0.012 6.37E-13 
rs4496335 2 113560946 closest IL1F10 T C 0.34 3209 -0.085 0.012 6.37E-13 
rs6741180 2 113560855 closest IL1F10 A G 0.34 3209 -0.085 0.012 6.37E-13 
rs12328766 2 113563209 closest IL1F10 G A 0.34 3209 -0.085 0.012 6.38E-13 
rs12329129 2 113563478 closest IL1F10 A G 0.34 3209 -0.085 0.012 6.38E-13 
rs12328368 2 113563615 closest IL1F10 G C 0.34 3209 -0.085 0.012 6.38E-13 
rs6730516 2 113565432 closest IL1RN T C 0.34 3209 -0.085 0.012 6.44E-13 
rs1446510 2 113567988 closest IL1RN T C 0.34 3209 -0.085 0.012 6.47E-13 
rs1446509 2 113567630 closest IL1RN T A 0.34 3209 -0.085 0.012 6.47E-13 
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rs6738239 2 113567263 closest IL1RN A C 0.34 3209 -0.085 0.012 6.47E-13 
rs13409360 2 113554573 closest IL1F10 A G 0.34 3209 -0.084 0.012 7.78E-13 
rs6734238 2 113557501 closest IL1F10 G A 0.34 3209 -0.084 0.012 1.06E-12 
rs6743376 2 113548804 IL1F10 C A 0.37 5303 0.056 0.008 2.28E-12 
rs315943 2 113610809 closest IL1RN G A 0.34 3209 -0.082 0.012 2.46E-12 
rs13409371 2 113554616 closest IL1F10 A G 0.40 3209 -0.083 0.012 3.83E-12 
rs4145013 2 113547159 IL1F10 G A 0.35 5306 0.055 0.008 5.91E-12 
rs7574159 2 113576232 IL1RN A G 0.33 3209 -0.082 0.012 1.24E-11 
rs17207494 2 113580481 IL1RN C A 0.33 3209 -0.082 0.012 1.34E-11 
rs10171849 2 113582305 IL1RN C A 0.33 3209 -0.082 0.012 1.35E-11 
rs13382561 2 113580007 IL1RN G A 0.33 3209 -0.082 0.012 1.37E-11 
rs13424580 2 113569035 closest IL1RN A G 0.33 3209 -0.081 0.012 1.37E-11 
rs6746979 2 113570591 closest IL1RN A T 0.33 3209 -0.081 0.012 1.38E-11 
rs7574427 2 113576509 IL1RN A G 0.33 3209 -0.082 0.012 1.39E-11 
rs11885498 2 113616648 closest IL1RN G A 0.36 3209 -0.078 0.012 2.53E-11 
rs2902452 2 113611987 closest IL1RN A C 0.36 3209 -0.078 0.012 2.80E-11 
rs6754298 2 113612684 closest IL1RN A T 0.36 3209 -0.078 0.012 2.85E-11 
rs1374281 2 113615260 closest IL1RN G C 0.36 3209 -0.078 0.012 2.86E-11 
rs895496 2 113615496 closest IL1RN T C 0.36 3209 -0.078 0.012 2.93E-11 
rs1530551 2 113534037 IL36RN T C 0.38 5307 0.050 0.008 1.08E-10 
rs380092 2 113605371 IL1RN T A 0.36 5308 0.052 0.008 1.13E-10 
rs2472188 2 113537285 IL36RN C G 0.38 5304 0.049 0.008 1.89E-10 
rs11123167 2 113623340 closest IL1RN C G 0.36 3209 -0.074 0.012 2.82E-10 
rs3827763 2 113547760 IL1F10 A G 0.30 5310 0.052 0.008 6.99E-10 
rs1867828 2 113485091 closest IL1F10 A G 0.26 5310 -0.052 0.009 2.27E-09 
rs3811050 2 113546644 IL1F10 T C 0.18 5310 -0.062 0.011 3.22E-09 
rs315952 2 113606775 IL1RN C T 0.35 5300 0.047 0.008 4.62E-09 
rs11678375 2 113552162 closest IL1F10 T C 0.43 3209 0.060 0.011 2.58E-08 
rs13386602 2 113551291 closest IL1F10 A C 0.43 3209 0.060 0.011 2.61E-08 
rs12469822 2 113547034 IL1F10 G A 0.44 3209 0.060 0.011 3.22E-08 
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Variants that passed the discovery P value threshold of 5.0x10
-8 
are shown. The two most significantly associated independent SNPs from the 
discovery meta-analysis (marked in bold) were then taken forward for replication. 
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Supplementary Table 2. Replication and combined meta-analysis results for the SNPs independently associated with circulating IL-1RA levels with 
YFS included in analyses.   
 
 
 
 
 
 
  
Marker name Chr Position (HG18) Gene 
Minor 
(coded) 
allele 
Major 
allele Mean MAF 
Replication  
N Effect SE P I
2
 (%) 
Meta-analysis 
model 
rs4251961 2 113590938 IL1RN C T 0.32 6802 -0.064 0.027 0.016 90.74 RE 
rs6759676 2 113552819 closest IL1F10 C T 0.44 6802 0.073 0.034 0.031 94.94 RE 
Marker name Chr Position (HG18) Gene 
Minor 
(coded) 
allele 
Major 
allele Mean MAF 
Combined 
N Effect SE P I
2
 (%) 
Meta-analysis 
model 
rs4251961 2 113590938 IL1RN C T 0.32 15894 -0.077 0.012 9.46E-11 79.72 RE 
rs6759676 2 113552819 closest IL1F10 C T 0.44 15933 0.068 0.013 9.14E-08 84.69 RE 
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Supplementary Figure 1. In silico functional analysis for rs6759676. 
 
 
 
 
A snapshot of the UCSC Genome Browser shows that rs6759676 falls within an region enriched for H3K27Ac histone acetylation (often found near 
active regulatory elements) in epidermal keratinocytes cells (pink peak) and human mammary epithelial cells (grey peak); within a DNase 
hypersensitive region (characteristic of open chromatin regions) in multiple cell lines; and also within STAT transcription factor binding sites.
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Supplementary Figure 2. In silico functional analysis for rs4251961.  
 
 
 
 
A snapshot of the UCSC Genome Browser shows that rs4251961 falls within a region enriched for the H3K27Ac histone acetylation mark (often 
found near active regulatory elements) in epidermal keratinocytes cells (pink peak) and human mammary epithelial cells (grey peak) 
(Supplementary Figure 2), upstream of the IL1RN gene. It is very close to regions enriched for transcription factor binding and DNase 
hypersensitivity, indicative of open chromatin. 
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Supplementary Figure 3.  Association of rs4251961 and rs6759676 with circulating fasting glucose, 2-hr glucose, HbA1c and 2-hr insulin in 
individual studies included in the discovery and replication analysis.  
 
A, B: fasting glucose; C, D: 2-hr glucose; E, F: HbA1c; G, H: 2-hr insulin. 
All analyses were adjusted for age, sex, BMI, waist-to-hip ratio and smoking. 
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Supplementary Figure 4.  Association of rs4251961 and rs6759676 with circulating IL-1RA levels in individual discovery and replication studies 
while YFS is included in the replication analysis.  
 
 
All analyses were adjusted for age, sex, BMI, waist-to-hip ratio and smoking. 
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